Cancer and neoplasms
Metabolic and Endocrine
Dissecting the Contribution of glucocorticoid metabolism in Mild Autonomous Cortisol Secretion: a randomised controlled trial of the 11β-HSD1 inhibitor SPI-62 (DC-MACS)
We will conduct a randomised,double-blind,placebo controlled,Phase 2 study to evaluate the effect of the selective 11β-HSD1 inhibitor,SPI-62,6mg once daily for 12-weeks,on metabolic,bone and cognitive phenotype in patients with adrenal adenomas and evidence of MACS.
40 patients with MACS will be recruited from tertiary referral endocrine centres. All participants will have baseline investigations performed before treatment. We will collect clinical data by collecting biological samples including serum,urine,adipose tissue and microdialysis,as well as questionnaires and cognitive function tests. All participants will have baseline ...
GO TO STUDY